EGFR-Mutated NSCLC: Evolving First-Line Treatment Landscape

In this opening segment, Dr. Sands sets the stage by asking the panel to describe the current treatment landscape for EGFR-mutated non-small cell lung cancer. Dr. Wakelee and Dr. Cooper discuss how recent advances have reshaped first-line treatment decisions, particularly with the growing role of targeted therapies and combination strategies. The conversation highlights how third-generation EGFR tyrosine kinase inhibitors remain foundational, while emerging data from key phase III trials such as FLAURA2 and MARIPOSA are influencing clinical practice. Dr. Wakelee further shares her approach to selecting between monotherapy and combination regimens, emphasizing the need to balance efficacy outcomes, including progression-free survival and CNS activity, with safety and tolerability. Overall, this segment provides a concise overview of how clinicians are incorporating evolving clinical evidence into real-world treatment decisions in EGFR-mutated NSCLC.